Company profilePharmaceutical#172 of 1,318 in Pakistan10 DRAP alerts

HOOVER PHARMACEUTICALS (PVT) LTD

Pharmaceutical company · 104 brands · 84 molecules

Ranked #60 of 137 companies in Anti-Infectives

104 registered products 46 pharmaceutical brands 84 distinct molecules 10 DRAP alerts

Company overview

104
registered products
46
pharmaceutical brands
84
distinct molecules
2
therapeutic classes
10
DRAP alerts

HOOVER PHARMACEUTICALS (PVT) LTD is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 104 product registrations across 84 distinct molecules. It is the 172nd largest registrant in Pakistan by product count, and ranks 60th of 137 in Anti-Infectives. Its portfolio is concentrated in Anti-Infectives and Antifungal For Dermatological. DRAP has issued 47 alerts involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by HOOVER

67 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Antifungal For Dermatological 2

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

61
ceilings with an approval date
0
not revised in 2+ years
2025
oldest approval year
202561

Top molecules by brand count

Omeprazole7 brands
Azithromycin5 brands
Clindamycin5 brands
Terbinafine5 brands
Cefixime4 brands
Ceftriaxone3 brands
Povidone-Iodine3 brands
Permethrin3 brands
Clotrimazole3 brands

Therapeutic classes

Anti-Infectives · 2Antifungal For Dermatological · 1

Conditions treated

General Infections · 1Fungal Infection · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official93 products · Rs 47.43 – Rs 902.88
Servaid2 products · Rs 176 – Rs 321
Median across source: Rs 313.63

Regulatory record

10 alerts in the DRAP feed we track.

23. Recall Alert – Class II – Drug Products – Provincial reports
2026-04-14
20. Rapid Alert – SPURIOUS DYDROGESTERONE TABLETS
2026-04-14
18. Rapid Alert – Spurious TERBIDERM FORTE TABLET (TERBINAFINE 250 mg) & GLANTRIM OPHTHALM
2026-04-14
08. Recall Alert (Class-II) – DTLs punjab declared substandard drug products.
2026-03-11
09. Rapid Alert – SPURIOUS CEFIXIME 400mg CAPSULE (Batch # LLM034)
2026-03-11
12. Rapid Alert – SPURIOUS CAPSULE GABICA 300 mg (BATCH NO. 518C27)
2026-03-11
13. Rapid Alert – SPURIOUS TABLET D-GEST DYDROGESTERONE 10 mg) (BATCH NO. DGH007)
2026-03-11
02. Recall Alert (Class-II) – Drug Products tested by DTL Punjab
2026-02-12

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

BIO LABS (PVT) LTD. holds 119 molecules not in this portfolio
000 I.UAmlodipineAprepitantAremetherArtemetherArtesunate
Atco Pharma International (Pvt) Ltd holds 213 molecules not in this portfolio
Acetylsalicylic AcidAcyclovirAdapaleneAdapleneAlbuterolAminophylline
MEDIATE PHARMACEUTICALS (PVT) LTD holds 98 molecules not in this portfolio
AcyclovirAlendronateAmlodipineAmoxicillinAmpicillinAmpicillin Base

Get the full profile for HOOVER

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.